Alcon AG vs Credo Technology Group Holding Ltd — how do they compare? Alcon AG trades at $73.34 (market cap $36.44B), while Credo Technology Group Holding Ltd trades at $271.53 (market cap $46.19B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and Alcon AG pays a 0.48% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| ALC | CRDO | |
|---|---|---|
Market Cap | $36.44B | $46.19B |
Sector | Health | Technology |
52-Week High | $90.12 | $302.52 |
52-Week Low | $62.02 | $87.81 |
Enterprise Value | $40.28B | $44.77B |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
CRDO trades at $257.10, up 7.15% today, with strong bullish momentum supported by technical indicators and positive analyst sentiment. The stock shows robust fundamentals with 157% revenue growth in Q4 2025 and consistent earnings beats. Recent news highlights Credo's strategic positioning in AI infrastructure, including contributions to the Open Compute Project and institutional investment increases.
Outlook remains positive with 86.7% analyst buy ratings and a $285.42 consensus price target, though premium valuations (P/E 98.7) and recent insider selling warrant caution. Key risks include customer concentration and execution challenges in the competitive AI hardware space.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →